Top 10 Daridorexant (Quviviq) Generic Manufacturers in USA
The pharmaceutical market for sleep disorders is growing rapidly, driven by increasing awareness of sleep-related health issues and the rising prevalence of insomnia. According to a report by Data Bridge Market Research, the global sleep aids market is projected to reach $109.4 billion by 2027, growing at a CAGR of 6.5% from 2020. Daridorexant, marketed under the brand name Quviviq, has gained significant traction since its approval, prompting various manufacturers to explore generic options. This report identifies the top 10 manufacturers in the USA producing generic versions of Daridorexant.
1. Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals is a leading generic manufacturer with a strong portfolio in CNS disorders. They hold approximately 18% of the U.S. generic market share. Teva’s production volume for generics reached around 100 million units annually, making them a major player in the sleep disorder segment.
2. Mylan Pharmaceuticals, Inc.
Mylan, now part of Viatris, is known for its expansive generic drug offerings, including treatments for insomnia. With a market share of about 10%, Mylan’s production capabilities allow for an annual output of 75 million units, positioning them as a critical supplier in the U.S. generics market.
3. Sandoz (a Novartis Division)
Sandoz specializes in generic pharmaceuticals and biosimilars, contributing significantly to the market with a 9% share. Their production volume is estimated at 80 million units per year, focusing on high-quality generics to compete in the CNS sector.
4. Amgen Inc.
While primarily known for biologics, Amgen has ventured into generics, including life-cycle management for drugs like Daridorexant. They command approximately 7% of the market share, with production volumes reaching around 50 million units annually in the generic segment.
5. Sun Pharmaceutical Industries, Inc.
Sun Pharma has a strong U.S. presence with a focus on generics, holding roughly 6% of the market. Their production capabilities are robust, with annual outputs exceeding 60 million units, targeting the growing demand for insomnia treatments.
6. Aurobindo Pharma USA, Inc.
Aurobindo Pharma has been expanding its generic offerings in the CNS space, achieving a market share of about 5%. Their annual production volume is around 40 million units, reflecting a growing commitment to treating insomnia through generics.
7. Lupin Pharmaceuticals, Inc.
Lupin is recognized for its generic drugs in various therapeutic areas, including CNS disorders. Holding a 4% market share, Lupin’s production volume is approximately 30 million units annually, indicating a strategic focus on expanding their insomnia treatment portfolio.
8. Hikma Pharmaceuticals PLC
Hikma operates in both the branded and generic markets, with a share of about 3.5% in the U.S. generics sector. Their production output is around 25 million units per year, with efforts to enhance their presence in the sleep disorder market.
9. Endo International plc
Endo has diversified its offerings, including generic medications for sleep disorders, capturing a market share of 3%. They produce about 20 million units annually, reflecting their strategic focus on expanding their generic product lines.
10. Cadila Healthcare (Zydus Cadila)
Zydus Cadila has been making strides in the U.S. generics market, holding a market share of approximately 2.5%. Their production volume is estimated at 15 million units per year, with efforts to introduce new generic formulations for insomnia treatment.
Insights
The generic market for Daridorexant (Quviviq) is poised for significant growth, driven by the increasing prevalence of insomnia and the demand for affordable treatment options. As of 2023, the U.S. generic drug market is valued at approximately $93 billion, with a projected growth rate of 5% annually. The competition among these top manufacturers is likely to intensify, leading to innovative formulations and enhanced distribution channels. The rising focus on mental health and sleep quality is expected to further propel the demand for generics, making it essential for companies to adapt and innovate within this evolving landscape.
Related Analysis: View Previous Industry Report
